NTRB · NutriBand Inc.
$4.50
-0.33 (-6.83%)
At close · Aug 26
Going-concern doubt
— cleared Jun 11, 2026
The latest filing states the doubt was alleviated.
“Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.”View the 10-Q filed Jun 11, 2026
Market Cap
$54.95M
Shares
12.16M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.04M
-4.8%
FY2026
Net Income
-$8.23M
+21.5%
FY2026
Gross Margin
27.81%
-6.9pp
FY2026
Operating Margin
-408.41%
+72.3pp
FY2026
Diluted EPS
-$2.58
-160.6%
FY2026
Operating Cash Flow
-$5.13M
-11%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.8M | $2.04M | $2.14M | $2.09M | $2.08M | $1.42M | $943.7K | $119.36K | $245.29K | — | — | |
| $1.29M | $1.47M | $1.4M | $1.22M | $1.33M | $917.84K | $627.38K | $549.11K | $288.3K | — | — | |
| — | $566.31K | $743.32K | $862.11K | $750.4K | $554.31K | $316.23K | — | — | — | — | |
| — | 27.81% | 34.74% | 41.34% | 36.08% | 38.98% | 33.51% | — | — | — | — | |
| $1.45M | $1.89M | $3.12M | $1.96M | $982.23K | $411.38K | — | — | — | — | — | |
| $7.21M | $6.99M | $4.31M | $3.77M | $3.92M | $4.02M | $2.91M | $1.79M | $3.29M | $171.95K | $151.26K | |
| — | $60.67K | $113.15K | $113.15K | $146.48K | $129.82K | — | $19.22K | — | — | — | |
| $170.49K | $193.8K | $285.05K | $287.72K | $330.14K | $308.74K | $160.11K | $72.19K | $37.01K | — | — | |
| — | $8.88M | $11.03M | $5.73M | — | $6.62M | $2.91M | $2.34M | $3.58M | $2.67M | — | |
| $9.96M | $10.35M | $12.42M | $6.96M | $6.55M | $7.53M | $3.54M | $2.34M | — | $2.67M | $151.26K | |
| -$8.16M | -$8.32M | -$10.28M | -$4.87M | -$4.48M | -$6.11M | -$2.6M | -$1.97M | -$3.33M | -$2.67M | -$151.26K | |
| — | -408.41% | -480.7% | -233.63% | -215.19% | -429.68% | -275.08% | -1649.94% | -1358.11% | — | — | |
| -$7.99M | -$8.12M | -$10M | -$4.58M | -$4.15M | -$5.8M | -$2.44M | -$1.9M | -$3.29M | — | — | |
| $21.66K | $22.54K | $21.41K | $75.82K | $8289 | $118.42K | $280.69K | $73.41K | — | — | — | |
| — | $110.86K | $191.67K | $16.85K | — | — | — | — | — | — | — | |
| $76.1K | $88.33K | -$197.77K | -$613.39K | $5.23M | $6.62M | -$336.88K | -$752.19K | — | — | — | |
| -$8.08M | -$8.23M | -$10.48M | -$5.49M | -$4.48M | -$6.18M | -$2.93M | -$2.72M | -$3.33M | -$2.67M | — | |
| -$8.08M | -$8.23M | -$10.48M | -$5.49M | -$4.48M | -$6.18M | -$2.93M | -$2.72M | -$3.33M | -$2.67M | -$151.26K | |
| — | -404.08% | -489.95% | -263.04% | -215.59% | -434.28% | -310.78% | -2280.11% | -1358.11% | — | — | |
| -$29.9M | -$30.04M | -$10.48M | — | -$4.48M | -$6.37M | — | — | — | — | — | |
| -$1.63M | — | — | — | — | — | — | -$2.72M | -$3.33M | -$2.67M | -$151.19K | |
| USD/shares | — | -$2.58 | -$0.99 | -$0.69 | -$0.53 | -$0.80 | -$0.44 | — | — | — | — |
| USD/shares | — | -$2.58 | -$0.99 | -$0.69 | -$0.53 | -$0.80 | — | — | — | — | — |
| shares | — | 11.64M | 10.61M | 7.95M | 8.46M | 7.93M | 6.73M | 6.32M | 6.24M | 22.4M | 24.73M |
| shares | — | 11.64M | 10.61M | 7.95M | 8.46M | 7.93M | 6.73M | 6.32M | 6.24M | 22.4M | 24.73M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.62×
EV/EBIT
—
Peer median 12.10×
P/E (TTM)
—
Peer median 8.71×
Peer medians compare against the 289 similar-size Biotechnology companies (of 534 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Pocono Pharmaceuticals | $2,036,651 | $2,139,537 | $1,920,280 |
| Four P Therapeutics | — | — | $165,034 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| United States | $2,029,021 | $2,139,537 | $2,085,314 | $2,079,609 |
| Non Us | $7,630 | — | — | — |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Sale of Goods | $2,036,651 | $2,139,537 | $1,920,280 |
| Service | — | — | $165,034 |
Key facts
CIK
1676047
CUSIP
67092M208
13F (30d)
18 filings
18 filers
Visit website
Investor relations